Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Reexamination Certificate
2005-04-19
2005-04-19
Shukla, Ram R. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
C424S093200, C435S320100
Reexamination Certificate
active
06881402
ABSTRACT:
A method for inhibiting apoptosis of a cell expressing a death receptor of the TNFR family is disclosed. The method involves treating the cell with a Receptor Internalization and Degradation (RID) protein complex containing RIDα (10.4K) and RIDβ (14.5K) proteins encoded by the E3 region of adenovirus. The cell can be treated by administering to the cell a polynucleotide expressing the RID complex or by administering to the cell a composition containing the RID complex. Compositions containing a RID complex are also disclosed. The compositions and method are useful in the treatment of cancer, degenerative and immune disorders, as well as in promoting survival of tissue transplants. An adenovirus vector for delivering the RID complex to cells is also disclosed.
REFERENCES:
patent: 4963481 (1990-10-01), de Villiers
patent: 6156306 (2000-12-01), Brownlee et al.
Deonarain, MP., “Ligand-targeted receptor-mediated vectors for gene delivery.” Exp. Opin. ther. Patents, vol. 8 (1): 53-69, 1998.*
Crystal, RG., “Transfer of genes to humans: Early lessons and obstacles to success.” Science, vol. 270 : 404-410, 1995.*
Miller et al., “Targeted vectors for gene therapy.” FASEB, vol. 9: 190-199, Feb. 1995.*
Eck et al., “Gene-based Therapy,” Goodman & Gilman's The Pharmacological Basis of Therapeutics- Ninth Edition, McGraw-Hill: 77-101, 1996.*
Deigner et al., “Modulating Apoptosis: Current Applications and Prospects for Future Drug Development.” Current Medicinal Chemistry, vol. 6: 399-414, 1999.*
Tio et al., “Gene therapy to prevent restenosis, the Boston experience.” Semin Intervent Cardiol, vol. 3: 205-210, 1998.*
Blau et al., “Molecular Medicine-Gene therapy- a Novel Form of Drug Delivery.” The New England Journal of Medicine, vol. 333 (18): 1204-1207, Nov. 1995.*
Special News Report, “Gene Therapy's Growing Pains.” Science, vol. 269: 1050-1055, Aug. 1995.*
Anderson, F., “Human Gene Therapy.” Nature, vol. 392 supp: 25-30, Apr. 1998.*
Verma et al., “Gene therapy—promises, problems and prospects.” Nature, vol. 389: 239-242, Sep. 1997.*
Carlin et al., Epidermal Growth Factor Receptor is Down-Regulated by a 10,400 MW Protein Encoded by the E3 Region of Adenovirus,Cell, 57:135-144 (1989(.
Clark et al., Molecular Pathways of CTL-mediated Cytotoxity,Immunological Reviews, 146:33-44 (1995).
Dimitrov et al., Adenovirus E3-10.4K/14.5K Protein Complex Inhjibits Tumor Necrosis Factor-Induced Translocation of Cytosolic Phospholipase A2to Membranes,J. of Virol., 71:2830-2837 (1997).
Efrat et al., Prolonged survival of pancreatic islet allografts mediated by adenovirus immunoregulatory transgenes,Proc. Natl. Acad. Sci. USA, 92:6947-6951 (1995).
Fejer et al., Characterization of Transgenic Mice Containing Adenovirus Early Region 3 Genomic , DNA,J. of Virol., 68:5871-5881 (1994).
French et al., Thyroiditis and hepatitis: Fas on the road to disease,Nature Med., 3(4):387-388 (1997).
Friesen et al., Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,Nature Med., 2(5):574-577 (1996).
Giordano et al., Potential Involvement of Fas and Its Ligand in the Pathogenesis of Hashimoto's Thyroiditis,Science, 275:960-963 (1997).
Hahne et al., Melanoma Cell Expression of Fas(Apo-1/CD95) Ligand: Implications for Tumor Immune Escape,Science, 274:1363-1366 (1996).
Hermiston et al., The Adenovirus E3-10.4K/14.5K Heterodimer, Renamed RID (Receptor Internalization and Degradation), Inhibits TNF-induced Apoptosis, Arachidonic Acid Release, Translocation of cPLA2to Membranes, and Fas-induced Apoptosis, and it Down-regulates Cell Surface Fas and EGF Receptor, Abstract presented at Small DNA Tumor Viruses Meeting, Jul. 9-14, 1996.
Hermiston et al., Deletion Mutation Analysis of the Adenvirus Type 2 E3-gp19K Protein: Identification of Sequences within the Endoplasmic Reticulum Lumenal Domain That Are Required for Class I Antigen Binding and Protection from Adenovirus-Specific Cytotoxic T Lymphocytes,Journal of Virology, 67(9):5289-5298 (1993).
Herrath et al., Expression of adenoviral E3 transgenes in β cells prevents autoimmune diabetes,Proc. Natl. Acad. Sci. USA, 94:9808-9813 (1997).
Ilan et al., Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression,Proc. Natl. Acad. Sci. USA, 94:2587-2592 (1997).
Kondo et al., Essential roles of the Fas Ligand in the development of hepatitis,Nature Medicine, 3(4):409-413 (1997).
Krajcsi et al., The Adenovirus E3-14.7K Protein and the E3-10.4K/14.5K Complex of Proteins, Which Independently Inhibit Tumor Necrosis Factor (TNF)-Induced Apoptosis, Also Independently Inhibit TNF-Induced Release of Arachidonic Acid,J. of Virol, 70(8):4904-4913 (1996).
Lau et al., Prevention of Islet Allograft Rejection with Engineered Myoblasts Expressing FasL in Mice,Science, 273:109-112 (1996).
Lenardo, Fas and the Art of Lymphocyte Maintenance,The Journal of Experimental Medicine, 183:721-724 (1996).
Nagata, Fas ligand and immune evasion,Nature Med., 2(12):1306-1307 (1996).
Nagata, Apoptosis by Death Factor,Cell, 88:355-365 (1997).
O'Connell et al., The Fas Counterattack: Fas-mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand,J. Exp. Med., 184:1075-1082 (1996).
Shisler et al., The Adenovirus E3-10.4K/14.5K Complex Mediates Loss of Cell Surface Fas (CD95) and Resistance to Fas-Induced Apoptosis,J. of Virol., 71:8299-8306 (1997).
Sparer et al., The Role of Human Adenovirus Early Region 3 Proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a Murine Pneumonia Model,J. of Virol., 70:2431-2439 (1996).
Stewart et al., The Adenovirus E3 10.4K and 14.5K Proteins, Which Function to Prevent Cytolysis by Tumor Necrosis Factor and To Down-Regulate the Epidermal Growth Factor Receptor, Are Localized in the Plasma Membrane,J. of Virol., 69:172-181 (1995).
Strand et al., Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells —A mechanism of immune evasion?,Nature Medicine, 2(12):1361-1366 (1996).
Tanaka et al., Fas ligand in human serum,Nature Medicine, 2(3): 317-322 (1996).
Tollefson et al., Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells,Nature, 392:726-730 (1998).
Tollefson et al., The 10,400- and 14,500-Dalton Proteins Encoded by Region E3 of Adenovirus Form a Complex and Function togetehr to Down-Regulate the Epidermal Growth Factor Receptor,J. of Virol., 65:3095-3105 (1991).
Williams, Tumor Cells Fight Back to Beat Immune System,Science, 274:1302 (1996).
Williams, Thyroid Disease: A Case of Cell Suicide?, Science, 275:926 (1997).
Wold, NIH Grant RO1 CA58538 pp. 1-2, 45-81 (Funded Jul. 18, 1997).
Saint Louis University
Shukla Ram R.
Thompson & Coburn LLP
LandOfFree
Inhibiting apoptosis with adenovirus RID protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibiting apoptosis with adenovirus RID protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibiting apoptosis with adenovirus RID protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3381683